Syntara (SNT) H2 2026 earnings summary

Executive summary

• Revenue from ordinary activities and other income decreased by 7.9% to $7.0 million for the year ended 30 June 2026 compared to the prior year.

• Net loss after tax increased by 13.6% to $9.0 million, driven by higher expenses and lower income from discontinued operations.

• No dividends were paid, recommended, or declared for the current or previous financial year.

• The company advanced its clinical pipeline, notably with amsulostat in myelofibrosis and myelodysplastic syndromes, and secured non-dilutive funding and capital raising.

Financial highlights

• Revenue and other income: $7.0 million, down from $7.6 million year-over-year.

• Net loss after tax: $9.0 million (2025: $7.9 million).

• Cash and cash equivalents at year-end: $13.6 million.

• Net tangible assets per share: 0.82 cents (2025: 0.97 cents).

• Research and Development Tax Incentive income: $4.7 million.

Outlook and guidance

• Multiple near-term clinical catalysts expected in FY2027, including data from MDS studies, SNT-4728 Phase 2 results, and the start of a pancreatic cancer program.

• Cash runway extended into Q3 of calendar 2027 following capital raising.

• Focus remains on advancing the diversified clinical pipeline and achieving value-creating milestones.